3 years ago

Clerkenwell Health Raises £2.1M to Open Europe's First Psychedelic Therapy Facility

  • Clerkenwell Health, a London-based clinical psychedelics startup, has raised £2.1 million in seed funding from Lionheart Ventures, Convergence Partners, and Exceptional Ventures

  • The funding will support the operations of the company’s clinical trials facility, Europe’s first commercial facility dedicated to psychedelic assisted therapies, which is set to open this Autumn

  • Clerkenwell Health is supporting North American drug developers entering the UK, including Toronto-based life sciences company Psyence, which has received approval from the MHRA to kick off the first trials at Clerkenwell’s London site.

      • ProblemHealthcare

      "There is a lack of infrastructure and expertise to conduct clinical trials for psychedelic assisted therapies, slowing down the development and adoption of these treatments."

      Solution

      "Clerkenwell Health provides a commercial clinical trials facility and services to support the design, delivery, and execution of psychedelic-assisted therapy trials, enabling faster development and adoption of these treatments."

      Covered on